July 2008

GB presents at Biosimilars Conference in Philadelphia
IBC held it’s 4th Biosimilars Conference in Philadelphia, Pennsylvania. GB CEO Matthew Chervenak gave a riveting presentation the opportunities and challenges for biologics in China, including discussion on the impact of the price in China, case studies, an outline of working businesses and sales models, and the road to FDA compliance and non-regulated markets.

May 2008

GB presents at Impact IV China Conference in Beijing
The Impact China: Pharmaceutical R&D Global Summit was held in Beijing, China. The conference was notable for its comprehensive coverage of vital issues in China’s R&D sector and the variety of companies in attendance. GB CEO Matthew Chervenak presented on the key opportunities in outsourcing and innovation in China’s rapidly evolving biotechnology industry.

May 2008

Jonathan Zifferblatt joins the GB team!
General Biologic is pleased to welcome Dr. Jon Zifferblatt, MD/MPH as Managing Director. Jon brings a unique combination of business, healthcare, and biopharmaceutical experience to GB’s multi-dimensional team. Jon has worked in management capacities in the pharmaceutical and investment banking sectors in both US and in China. Prior to joining GB, he was a Vice President at ChinaVest, a merchant bank headquartered in Shanghai. Dr. Zifferblatt earned his MPH and his MBA from the University of California, Berkeley. He received his MD from the University of California, San Diego School of Medicine.

April 2008

GB presents at Pharma Delegates in Tokyo
GB CEP Matthew Chervenak presented to an audience of Japanese pharmaceutical executives at Pharma Delegates at the American Club in Tokyo, Japan. Chervenak covered China’s rapidly expanding pharmaceutical market and industry, investment opportunities, and recent transactions in the country. Options for Japan’s pharmaceutical companies were presented in terms of market, sourcing, and R&D.

February 2008

GB presents at IBC Antibody Engineering Conference
IBC’s Antibody Engineering Conference was held this month in Singapore. GB CEO Matthew Chervenak gave a talk on the tremendous strides that have been made in China’s antibody industry over the past few years, and spoke on the market and R&D opportunities for Chinese and multinationals companies.

February 2008

GB Moves to New Office
GB moved to a new, expanded office location near Shanghai’s XinTianDi. Gong strike to announce all visitors. Suite 301, Building 2, 169 Mengzi Road, Shanghai, P.R. China 200023,. Phone +86 21 5302-2951, Fax +86 21 5302-2950.

January 2008

GB presents at Business Alliance FastTrack Forum
Business Alliance’s FastTrack Forum was held in Tysons Corner, Virginia this month. The Forum included discussion of market and service opportunities in China. GB CEO Matthew Chervenak presented on opportunities for the pharmaceuticals and biotechnology industry.

January 2008

GB publishes China Biotech 2008
GB released China Biotech 2008 this month. Updated and expanded from the 2006 edition, this report provides an in depth look at biotechnology R&D in China, industry statistics and indicators, and an authoritative directory of biotechnology companies. China Biotech 2008 is essential for understanding China’s emerging innovators, identifying potential clients and partners, and staying abreast of developments in this dynamic industry.

January 2008

GB publishes China Molecular Diagnostics report
GB released its report focusing on Molecular Diagnostics this month. Molecular Diagnostic industry players, investors, buyers, and vendors will benefit from this report and database. The material includes market assessments, technology focus areas, industry trends and policy updates. The database includes more than 100 companies providing molecular diagnostic products and services in China. More than 50 Chinese domestic and multinational kit & instrument manufacturers are included. The database also includes contacts at key distributors and service providers.

December 2007

GB releases the China Vaccine report
GB published China Vaccine 2008, providing an in depth analysis of the human use vaccine industry and market in China. The markets analysis covers the private payer sector, as well as providing an in depth look at the National Immunization Program, and the impact of the 10-fold increase in budget announced in 2007. Industry coverage includes profiles and analysis of the major domestic companies and research institutes. R&D and major technology initiatives are also addressed in the report.

August 2007

GB presents at AmCham’s Healthcare and Science & Technology Committee
The American Chamber of Commerce in Shanghai’s Healthcare and Science & Technology Committees held Moving from “Made in China” to “Made by China”: The Challenges & Opportunities of China’s Focus on Innovation, exploring the topic of innovation in China. GB CEO Matthew Chervenak presented on this topic from the MNC perspective with a focus on the healthcare industry. Biotechnology companies, research at China’s institutes and universities, and licensing transactions were addressed.

April 2007

GB releases new edition of China Antibodies report
GB released its updated and expanded China Antibody report, an essential resource for companies, investors, and entrepreneurs interested in accessing China's antibody industry. This report offers a comprehensive industry overview and market analysis, together with a directory of China’s antibody-related enterprises. GB analysts deliver detailed case studies of industry leaders, along with company profiles. Cost data is included and large-scale manufacturing is also addressed.

March 1, 2005

GB publishes its report on Bio-Distributors in China
GB analysts release "Bio-Distributors China 2005", a fundamental resource for life science suppliers seeking to reach customers in China. The report offers an overview of the industry environment for China's more than 180 distributors. "This report provides the foundation from which companies may craft an informed distribution strategy that maximizes potential in this rapidly changing market." says GB President, Matthew Chervenak.

February 1, 2005

GB releases its report on the antibody industry in China
"Antibodies in China" is an essential resource for companies, investors, and entrepreneurs interested in accessing China's antibody industry. This report offers a comprehensive overview and market analysis, together with a directory of over 30 antibody-related enterprises. GB analysts deliver detailed case studies of industry leaders, along with company profiles. Cost data is included and large-scale manufacturing is also addressed.

December 15, 2004

GB's China Pipeline featured in Nature Magazine article
In December's issue of Nature Magazine, Sabine Lou?t uses GB's unique China Pipeline Report as a jumping off point in a close look at China's burgeoning biotech industry. The article, "Can China bring its own pipeline to the market?", focuses on the opportunities and dangers available to industry players and investors, in a time of rapid innovation and strengthening government regulation.

December 13, 2004

GB publishes Bio-Services in China
GB published Bio-Services in China today, the essential starting point for any research enterprise, investor, or entrepreneur looking to increase R&D productivity and reduce costs through outsourcing. The report includes an overview of the industry, cost comparisons, 8 services categories with company listings and critical equipment employed, 3 case studies, 15 profiles, and a directory of 53 Chinese biotech service companies. As evidenced by Invitrogen's acquisition of Bioasia, there has never been a better time to contemplate the advantages China can bring to your organization.

November 10, 2004

GB publishes Emerging Bio-equipment Manufacturers in China 2004
GB published Emerging Bio-Equipment Manufacturers in China 2004 today, a directory of over 130 Chinese manufacturers, an overview and analysis of the emerging life science laboratory equipment industry in China, 20 profiles of leading companies, and case studies of two typical industry leaders. The publication is essential for multinational life science equipment manufacturers interested in sourcing, OEM or following China's growing industry.

November 10, 2004

GB publishes Reagent & Consumable Manufacturers, China 2004
GB published Reagent and Consumable Manufacturers today, which includes an overview and analysis of the emerging life science reagent and consumable industry in china, a complete directory of over 55 reagent and 30 consumable manufacturers, and 10 profiles of leading companies in the industry. The publication provides a comprehensive resource for multinational life science reagent and consumable manufacturers interested in sourcing, OEM, or following the industry.

October 22, 2004

GB presents at Environmental Biotechnology meeting
GB presented at China's Environmental Microbiology Symposium 2004 to a crowd of scientists and aspiring entrepreneurs. The talk, addressing the market for remediation and other environmental biotechnologies, was followed by talks on entrepreneurship by leadership from Siji Biotechnology.

October 20, 2004

GB publishes Pipeline China 2004, the first collection of innovative drug candidates developed in China
GB published Pipeline China 2004 today, highlighting over 130 new drugs under development in China. The report is a result of extensive research by GB staff members and addresses biologics and small molecules in preclinical and clinical development in China. The publication is essential for business development professionals at pharmaceutical and biotechnology companies interested in potential partnership with Chinese innovators.

September 15, 2004

GB publishes China Biotech 2004, an essential starting point for anyone interested in China\'s emerging biotechnology industry
GB published China Biotech 2004, a directory of the over 250 biotechnology companies and a 30 page overview of biotechnology development in China. The publication focuses on what has been accomplished and what remains to be done in China's fast-growing biotechnology industry.

July 30, 2004

General Biologic updates website, publications available for online purchase
General Biologic completed an update of its website today, adding functionality and information relevant to its client base. New sections include content that explains our services for investors, biotechnology and pharmaceutical companies, and suppliers to the biotechnology industry. Concurrently with the website, GB has initiated an email-based newsletter that will address the Chinese biotechnology industry growth and development.

June 6, 2004

General Biologic becomes one of the few Chinese members of the Biotechnology Industry Association (BIO)
General Biologic has become one of the only companies with primary operations in China to join BIO. We look forward to working together with other members of the organization to address common issues that relate to the biotechnology industry as a whole, and China in particular.